

Maria Teresa Melucci

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3198416/maria-teresa-melucci-publications-by-citations.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|-------------------|-------------------------|----------------|-----------------|
| 36 papers | 1,891 citations | 19 h-index | 38 g-index |
| 38 ext. papers | 2,138 ext. citations | 4.8 avg, IF | 3.71 L-index |

| # | Paper | IF | Citations |
|----|---|-----|-----------|
| 36 | Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>OncImmunology</i> , 2014 , 3, e28780 | 7.2 | 259 |
| 35 | Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014 , 63, 675-83 | 7.4 | 205 |
| 34 | Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7660-8 | 2.2 | 191 |
| 33 | Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 304-11 | 2.2 | 102 |
| 32 | Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. <i>Journal of Clinical Oncology</i> , 2003 , 21, 767-73 | 2.2 | 81 |
| 31 | Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets. <i>Frontiers in Oncology</i> , 2015 , 5, 183 | 5.3 | 62 |
| 30 | BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. <i>Journal of Clinical Oncology</i> , 2004 , 22, 286-92 | 2.2 | 47 |
| 29 | Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. <i>Melanoma Research</i> , 2005 , 15, 235-44 | 3.3 | 45 |
| 28 | Sensitivity and specificity of epiluminescence microscopy: evaluation on a sample of 2731 excised cutaneous pigmented lesions. The Melanoma Cooperative Study. <i>British Journal of Dermatology</i> , 2000 , 142, 893-8 | 4 | 40 |
| 27 | Definition of the role of chromosome 9p21 in sporadic melanoma through genetic analysis of primary tumours and their metastases. The Melanoma Cooperative Group. <i>British Journal of Cancer</i> , 2000 , 83, 1707-14 | 8.7 | 39 |
| 26 | Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. <i>Melanoma Research</i> , 2003 , 13, 167-70 | 3.3 | 32 |
| 25 | Unexpected distribution of cKIT and BRAF mutations among southern Italian patients with sinonasal melanoma. <i>Dermatology</i> , 2013 , 226, 279-84 | 4.4 | 31 |
| 24 | NEMO-binding domain peptide inhibits proliferation of human melanoma cells. <i>Cancer Letters</i> , 2009 , 274, 331-6 | 9.9 | 29 |
| 23 | The immune-related role of BRAF in melanoma. <i>Molecular Oncology</i> , 2015 , 9, 93-104 | 7.9 | 26 |
| 22 | Issues affecting molecular staging in the management of patients with melanoma. <i>Journal of Cellular and Molecular Medicine</i> , 2007 , 11, 1052-68 | 5.6 | 26 |
| 21 | Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 325-32 | 4.5 | 23 |
| 20 | Epiluminescence microscopy as a useful approach in the early diagnosis of cutaneous malignant melanoma. <i>Melanoma Research</i> , 1998 , 8, 529-37 | 3.3 | 23 |

| | | | |
|----|---|------|----|
| 19 | Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma. <i>Oncolmmunology</i> , 2017 , 6, e1283462 | 7.2 | 21 |
| 18 | Cisplatin, dacarbazine, and fotemustine plus interferon γ in patients with advanced malignant melanoma. <i>Cancer</i> , 2000 , 89, 2630-2636 | 6.4 | 19 |
| 17 | Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. <i>Oncology Reports</i> , 2011 , 25, 1495-502 | 3.5 | 17 |
| 16 | Clinical significance of PCR-positive mRNA markers in peripheral blood and regional nodes of malignant melanoma patients. Melanoma Cooperative Group. <i>Recent Results in Cancer Research</i> , 2001 , 158, 200-3 | 1.5 | 17 |
| 15 | Phenotype characterization of human melanoma cells resistant to dabrafenib. <i>Oncology Reports</i> , 2017 , 38, 2741-2751 | 3.5 | 16 |
| 14 | Molecular classification of patients with malignant melanoma for new therapeutic strategies. <i>Journal of Clinical Oncology</i> , 2007 , 25, e20-1 | 2.2 | 12 |
| 13 | Low Levels of Genetic Heterogeneity in Matched Lymph Node Metastases from Patients with Melanoma. <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1917-1920 | 4.3 | 11 |
| 12 | Mutation analysis of candidate genes in melanoma-prone families: evidence of different pathogenetic mechanisms at chromosome 9P21. <i>Melanoma Research</i> , 2003 , 13, 571-9 | 3.3 | 10 |
| 11 | Targeting Bcl-2 protein in treatment of melanoma still requires further clarifications. <i>Annals of Oncology</i> , 2008 , 19, 2092-3 | 10.3 | 8 |
| 10 | Adjuvant treatment of malignant melanoma: where are we?. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 57, 45-52 | 7 | 8 |
| 9 | Adjuvant therapy of cutaneous melanoma. <i>Lancet, The</i> , 1999 , 353, 328 | 4.0 | 8 |
| 8 | Mutations in ERBB4 may have a minor role in melanoma pathogenesis. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 1685-7 | 4.3 | 7 |
| 7 | The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients. <i>Annals of Oncology</i> , 2010 , 21, 1379-1380 | 10.3 | 5 |
| 6 | Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment. <i>Annals of Oncology</i> , 2000 , 11, 1504 | 10.3 | 4 |
| 5 | Adjuvant therapy of melanoma: what's new?. <i>Melanoma Research</i> , 2002 , 12, 293-6 | 3.3 | 4 |
| 4 | Epidemiological and genetic factors underlying melanoma development in Italy. <i>Melanoma Management</i> , 2015 , 2, 149-163 | 2.1 | 3 |
| 3 | Circulating melanoma-associated markers detected by RT-PCR in patients with classic Kaposi's sarcoma. <i>Annals of Oncology</i> , 2000 , 11, 635-6 | 10.3 | 2 |
| 2 | Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma. Melanoma Cooperative Group. <i>Annals of Oncology</i> , 2000 , 11, 487-90 | 10.3 | 1 |

1 Mobile hospital rooms to fight melanoma. *Melanoma Research*, **2001**, 11, 83-4

3.3